Trial Profile
Cost effectiveness of switching from HAART to darunavir + ritonavir, with versus without two non-nucleoside reverse transcriptase inhibitors, in HIV-positive patients in Spain
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2010
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Non-nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- 13 Dec 2010 New trial record